PeerView Oncology
Managing EGFR+ NSCLC With CNS Metastases: Is There a Difference in Clinical Benefit Between 1st Generation EGFR TKIs vs. Osimertinib?
By
PeerView Oncology
FEATURING
Sandip Patel
By
PeerView Oncology
FEATURING
Sandip Patel
Login to view comments.
Click here to Login